

**AMENDMENTS TO THE CLAIMS**

Please add claim 21 as follows:

1-6. (Previously Cancelled)

7. (Previously Amended) A method of treating a subject having type C viral hepatitis comprising administering, to the subject, by the peroral route, an oral liquid formulation of human  $\alpha$ -interferon at a daily dosage of between 100 and 500 IU.

8. (Previously Cancelled)

9. (Original) The method of claim 7 wherein the human  $\alpha$ -interferon is obtained from a lymphoblastoid cell culture.

10. (Previously Cancelled)

11. (Previously Amended) The method of claim 7 wherein the human  $\alpha$ -interferon is obtained from lymphocyte cells.

12. (Previously Cancelled)

13. (Original) The method of claim 7 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

14. (Previously Cancelled)

15. (Original) The method of claim 9 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

16. (Previously Cancelled)

17. (Original) The method of claim 11 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

18-20. (Previously Cancelled)

21. (New) A method of treating a subject having type C viral hepatitis comprising administering to the subject a daily dose of a liquid formulation of human  $\alpha$ -interferon, wherein the daily dose is administered by a peroral route, and wherein the daily dose is between 100 and 500 IU.